focus -WSS

focus

author：fashion 2025-10-01 17:56:41 - browse：8148

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Alabama IVF ruling threatens families facing fatal genetic disease

WSS

Ed Silverman on new gene therapies, biosimilars, coffee, and more

A Theranos scientist

A Theranos scientist

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

A solution to the after

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

leisure time

focus

focus

At least 13 dead in Texas as scorching temps continue

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

Wildfire smoke exposes gaps in outdoor worker protections

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

BioMarin wins approval for gene therapy to treat hemophilia A

Obesity drugs seen as possible treatment for liver disease MASH

Hollywood unions extend contract negotiations for actors

Flagship, Pfizer team up in deal worth up to $7 billion

Continuity nursing helped my family in our darkest PICU moments

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

hotspot

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

A Theranos scientist

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Biden administration sends mixed signals on US soldier who crossed into North Korea

explore

explore

leisure time

Wikipedia